Literature DB >> 19038285

Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis.

Julia Albrecht1, Sven F Garbade, Peter Burgard.   

Abstract

Although pathogenesis of phenylketonuria is not completely understood, a low phenylalanine diet is effective to prevent severe neurological impairment, mental retardation and behavioural difficulties. Treatment recommendations heavily rely on neuropsychological research; however, single study results are ambiguous, what is reflected in substantial variation of US, British, German, Dutch and French recommendations for blood phenylalanine concentrations for adolescents and adults. We conducted a meta-analysis estimating the influence of age, phenylalanine level, and type of neuropsychological test on effect sizes (standardized differences between controls and patients) of computer-based speed measurements in phenylketonuric patients. The effect of blood phenylalanine level on effect size was more pronounced in children and adolescents than in adults, with choice reaction time being particularly sensitive for phenylalanine concentrations. Results corroborate all recommendations for children. With the exception of the US and Dutch recommendations, all recommendations for adolescents seem to be too liberal. The same effect size is predicted for adult phenylalanine concentrations between 750 and 1500mumol/L not suggesting a preference for any of the published treatment recommendations for adulthood.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19038285     DOI: 10.1016/j.neubiorev.2008.11.001

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  29 in total

Review 1.  Phenylketonuria: a 21st century perspective.

Authors:  Francjan J van Spronsen
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

2.  Outcomes of phenylketonuria with relevance to follow-up.

Authors:  F J van Spronsen; A Bélanger-Quintana
Journal:  JIMD Rep       Date:  2011-06-22

3.  Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria.

Authors:  Anna Hood; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desirée A White
Journal:  Mol Genet Metab       Date:  2014-01-31       Impact factor: 4.797

4.  The influence of blood phenylalanine levels on neurocognitive function in adult PKU patients.

Authors:  A Bartus; F Palasti; E Juhasz; E Kiss; E Simonova; Cs Sumanszki; P Reismann
Journal:  Metab Brain Dis       Date:  2018-06-12       Impact factor: 3.584

5.  Sapropterin hydrochloride: enzyme enhancement therapy for phenylketonuria.

Authors:  Robin Lachmann
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

6.  The Comparison of Iodine-Type and MnO2-Type Oxidation for Measuring the Levels of Urine Neopterin and Biopterin in Patients with Hyperphenylalaninemia: A Descriptive-Analytic Study in Iran.

Authors:  Atena Askarizadeh; Shohreh Khatami; Soghra Rouhi Dehnabeh
Journal:  Indian J Clin Biochem       Date:  2018-08-23

7.  Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases.

Authors:  T Mlčoch; R Puda; P Ješina; M Lhotáková; Š Štěrbová; T Doležal
Journal:  Eur J Clin Nutr       Date:  2017-06-28       Impact factor: 4.016

8.  Commentary: What degree of hyperphenylalaninaemia requires treatment?

Authors:  R J Pollitt
Journal:  J Inherit Metab Dis       Date:  2012-06-21       Impact factor: 4.982

9.  Dietary treatment of phenylketonuria: the effect of phenylalanine on reaction time.

Authors:  Charlotte Dawson; Elaine Murphy; Charlé Maritz; Heidi Chan; Charlotte Ellerton; R H S Carpenter; Robin H Lachmann
Journal:  J Inherit Metab Dis       Date:  2011-02-03       Impact factor: 4.982

10.  Processing speed and executive abilities in children with phenylketonuria.

Authors:  Alicia L Janos; Dorothy K Grange; Robert D Steiner; Desirée A White
Journal:  Neuropsychology       Date:  2012-08-06       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.